Corrêa Fernando-Aguiar, de Arruda José-Alcides-Almeida, Drumond Victor-Zanetti, Cepeda Isadora-Vilas-Boas, Tarquinio Sandra-Beatriz-Chaves, Silva Tarcília-Aparecida, Abreu Lucas-Guimarães, Rivero Elena-Riet-Correa, Mesquita Ricardo-Alves, Etges Adriana
Postgraduate Program in Dentistry, Universidade Federal de Pelotas, Pelotas, Brazil.
Department of Oral Diagnosis and Pathology, School of Dentistry, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
J Clin Exp Dent. 2024 Jul 1;16(7):e885-e897. doi: 10.4317/jced.61490. eCollection 2024 Jul.
Pharmacological therapy has been used as an alternative or complementary approach to surgery in central giant cell granuloma (CGCG) of the jaws. This systematic review examined the effectiveness of pharmacological therapy for CGCG of the jaws, focusing on clinical outcomes.
Electronic searches were performed in six databases. Case reports and/or cases series were included. The Kaplan-Meier survival analysis method was used to evaluate outcomes related to clinical resolution and recurrence. The risk of bias was assessed using the Joanna Briggs Institute tool.
A total of 74 studies comprising 205 cases of CGCG were included. About 65.4% of cases occurred in individuals under 20 years of age. Most of the treated patients were women (61%) and the mandible (72.2%) was the most reported site. Curettage and enucleation before or after pharmacological therapy were reported in 28.3% and 19% of cases, respectively. The main pharmacological agent used was triamcinolone (37.5%). Complete resolution of CGCG was reported at a rate of 77.1%, while side effects were experienced by 9.8% of individuals. The recurrence rate was 6.8%.
Pharmacological therapy may be an effective and safe option for managing CGCG, especially in the young population. Although the overall success rate in achieving complete resolution is encouraging, further controlled studies are needed to refine drug selection and protocols. Calcitonin, Central giant cell lesion, Denosumab, Interferon, Pharmacological therapy, Triamcinolone.
药物治疗已被用作颌骨中央巨细胞肉芽肿（CGCG）手术的替代或补充方法。本系统评价研究了药物治疗颌骨CGCG的有效性，重点关注临床结局。
在六个数据库中进行电子检索。纳入病例报告和/或病例系列。采用Kaplan-Meier生存分析方法评估与临床缓解和复发相关的结局。使用乔安娜·布里格斯研究所工具评估偏倚风险。
共纳入74项研究，包括205例CGCG病例。约65.4%的病例发生在20岁以下个体。大多数接受治疗的患者为女性（61%），下颌骨（72.2%）是最常报道的部位。分别有28.3%和19%的病例报告在药物治疗前或后进行了刮除术和摘除术。使用的主要药物是曲安奈德（37.5%）。CGCG完全缓解率为77.1%，9.8%的个体出现了副作用。复发率为6.8%。
药物治疗可能是管理CGCG的一种有效且安全的选择，尤其是在年轻人群中。尽管实现完全缓解的总体成功率令人鼓舞，但仍需要进一步的对照研究来优化药物选择和方案。降钙素、中央巨细胞病变、地诺单抗、干扰素、药物治疗、曲安奈德
